Compare WKHS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | INTS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | WKHS | INTS |
|---|---|---|
| Price | $5.30 | $0.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $21.00 | $4.33 |
| AVG Volume (30 Days) | 381.8K | ★ 3.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,620,296.00 | N/A |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $5.10 | $0.19 |
| 52 Week High | $139.70 | $3.17 |
| Indicator | WKHS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 47.25 |
| Support Level | $5.10 | $0.40 |
| Resistance Level | $6.00 | $0.43 |
| Average True Range (ATR) | 0.87 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 41.30 | 20.02 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.